Services
Online Inquiry
For research use only. Not intended for any clinical use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Non-Human Primate (NHP) Single-Dose & Repeat-Dose Toxicology Study Service
Are you currently facing complex safety assessment challenges for your novel biologic or gene therapy? Creative Biolabs' Non-Human Primate Single-Dose & Repeat-Dose In Vivo Toxicology Service helps you accelerate your drug development pipeline by providing robust, regulatory-grade safety data. We leverage our advanced primate models and comprehensive in-house capabilities to solve the critical challenge of translating preclinical findings to human safety, enabling your team to make confident, data-driven decisions.
Introduction of NHP In Vivo Toxicology Studies Service
In the dynamic world of biopharmaceutical innovation, the path from drug discovery to clinical trial is paved with rigorous safety assessments. In vivo toxicology studies are the non-negotiable foundation of this process, providing the essential safety blueprint required for regulatory approval. Given their unparalleled physiological, genetic, and immunological similarities to humans, non-human primates (NHPs) are the model of choice for these critical studies. This is particularly true for biologics such as monoclonal antibodies, gene therapies, and vaccines, where a specific human-like target or immune response is required for accurate safety profiling.
What Our Service Is
Our service provides comprehensive single-dose and repeat-dose toxicology studies in NHPs.
- Single-Dose Studies: Also known as acute toxicity studies, these are designed to assess the immediate effects of a single, high-dose administration. They are crucial for establishing the Maximum Tolerated Dose (MTD) and identifying a drug's preliminary toxicity profile. This data is vital for setting a safe starting dose for Phase I clinical trials.
- Repeat-Dose Studies: These long-term studies evaluate the cumulative effects of repeated drug administration over an extended period, typically 28 or 90 days.
Why Choose Us?
- Pain Point: The high risk of failure and unforeseen toxicity in clinical trials.
We provide highly translatable safety data that accurately predicts human response, significantly de-risking your First-in-Human (FIH) clinical trials and protecting your investment.
- Pain Point: Translational challenges when moving from preclinical models to humans.
By utilizing NHPs, we overcome the limitations of rodent models, ensuring that the pharmacological and toxicological data is directly relevant to your human patient population.
- Pain Point: Delays and inefficiencies in the drug development timeline.
Our streamlined operational processes and experienced team ensure a rapid turnaround, from study design to final report, helping you accelerate your journey from the lab to the clinic.
Key Benefits of Our Service
The success of your drug candidate hinges on the quality and integrity of its preclinical safety data. Creative Biolabs provides a distinct advantage by combining deep scientific expertise with a world-class operational platform. Our in-house NHP resources and comprehensive technical capabilities ensure that your study is conducted with the utmost precision and efficiency.
- Unrivaled Species Relevance: Our NHP models offer a high degree of translational relevance, accurately predicting human responses to complex biologics. This minimizes the risk of unforeseen toxicities in clinical trials, saving you time and resources.
- Efficient Response Speed: Our streamlined internal processes and dedicated study directors ensure rapid study initiation and consistent communication, keeping your project on track and on time.
- Comprehensive Customization: We work closely with your team to design a study that is perfectly tailored to your compound's unique mechanism of action and your specific regulatory goals. We can accommodate various routes of administration, from intravenous to topical.
How Creative Biolabs' Service Can Assist Your Project?
Our NHP toxicology service is more than just a test; it is a strategic partnership designed to provide clear, actionable insights into your compound's safety profile. We deliver a complete solution, from study design to final report, allowing you to confidently move toward human clinical trials.
01
Required Starting Materials
02
Study Design & Protocol Approval
03
In-Life Phase
04
Endpoint Analysis
05
Data Compilation & QA/QC
06
Draft and Final Report Generation
Key Deliverables
- Final Report: A comprehensive written report including methodology, results, discussion, and conclusions.
- Raw Data: All original data from in-life monitoring, clinical pathology, and histopathology.
- Toxicokinetics & Statistical Analysis: Detailed analysis of drug exposure and dose-response relationships.
- Archived Tissue Samples: Preserved tissue blocks and slides for future reference or re-analysis.
- Digital Imaging: High-resolution digital scans of histopathology slides.
Capabilities & Partnerships
Service-Specific Data
- Annual Sample Size: Over 50,000 samples analyzed per year.
- Turnaround Time (TAT): Typical turnaround of 2 weeks for bioanalytical results.
- Study Pass Rate: 99%+ success rate in meeting study endpoints.
Our Valued Partners
Frequently Asked Questions
Q: Why are NHPs the right model for my biologic?
A: NHPs share a high degree of genetic and physiological similarity with humans. For many biologics, such as monoclonal antibodies, the drug's target is not present or is not functionally relevant in other species like rodents. Using NHPs ensures that the safety data you generate is directly translatable to humans, providing the confidence needed for a successful clinical trial application.
Q: How do you choose the right dose for my study?
A: Dose selection is a collaborative, science-driven process. We use all available data—from your preliminary in-vitro and non-GLP studies—to identify an appropriate starting dose and escalation schedule. Our goal is to select a dose range that will identify the No-Observed-Adverse-Effect-Level (NOAEL) while maintaining the well-being of the animals, giving you the best data for your project.
Q: What are the key differences between a single-dose and a repeat-dose study?
A: A single-dose study is a preliminary screen to understand acute toxicity and determine the maximum tolerated dose. A repeat-dose study, which is often a regulatory requirement, provides a much more comprehensive look at toxicity after repeated exposure. This helps identify potential long-term, cumulative, or delayed effects that are critical for human safety.
Q: How does Creative Biolabs ensure animal welfare?
A: Animal welfare is our highest priority. Our facilities are fully accredited, and all studies are reviewed. Our expert veterinarians and animal care technicians provide 24/7 care, ensuring that all animals are treated humanely and studies are conducted ethically, in full compliance with all regulations.
Contact Us
Creative Biolabs is your trusted partner for navigating the complexities of preclinical toxicology. Our world-class NHP In Vivo Toxicology Service provides the reliable, regulatory-grade safety data you need to confidently advance your drug candidate. To learn more about our services and discuss how we can tailor a solution to your specific project needs, please reach out to our team of experts.